Gilead Sciencesvs.Incyte
GILD vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 7.0× larger than Incyte by market cap; year to date, Incyte leads (+18.2% vs +5.8%).
Side by side
| GILD | INCY | |
|---|---|---|
| Market cap | $162B | $23.1B |
| Price | $129.83 | $116.71 |
| Today | −3.7% | −1.5% |
| Return YTD | +5.8% | +18.2% |
| Return 1Y | +13.3% | +65.9% |
| P/E | 17.5 | 16.1 |
| P/S | 5.4 | 4.3 |
| P/B | 6.9 | 4.1 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
Gilead SciencesGILD
American biotech company and global leader in HIV treatment, with a growing oncology portfolio.
Full GILD profile →More comparisons in Biotech & innovation
See where GILD and INCY sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →